Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate after denosumab discontinuation to suppress rebound bone turnover
2019-003570-11Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alendronate in High bone turnover (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Maintenance of CTx-I within premenopausal reference range at 48 weeks. Started Sep 2019; status: completed.
02
Drugs
alendronate
03
Conditions
High bone turnover
Beyond the preview
Go deeper on 2019-003570-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003570-11.